TNM classification of malignant tumors (Breast Cancer Study Group)

Masataka Sawaki, Tadahiko Shien, Hiroji Iwata

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)

Abstract

The eighth editions of the primary tumor, lymph node and metastasis classifications for breast cancer issued by the American Joint Commission of Cancer and the Union for International Cancer Control were revised in 2017. The major change made by the American Joint Commission of Cancer is to incorporate biological factors such as estrogen and progesterone receptor, human epidermal growth factor receptor 2, histological grade and multigene prognostic assays, into the staging system. Tumor biomarkers and low recurrence scores confirmed by multigene prognostic assays change the staging. Minor changes are to add the post-neoadjuvant therapy clinical and pathological classification and to define the size of tumor, lymph node and metastasis components more precisely. Little has changed in the Union for International Cancer Control. We have identified key points of change in both eighth editions of the tumor, lymph node and metastasis classifications and we discuss possible problems which may arise when they are adopted in Japanese practice, as well as future directions.

Original languageEnglish
Pages (from-to)228-231
Number of pages4
JournalJapanese journal of clinical oncology
Volume49
Issue number3
DOIs
Publication statusPublished - Mar 1 2019

Keywords

  • AJCC
  • Breast cancer
  • Eighth edition
  • TNM classification
  • UICC

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'TNM classification of malignant tumors (Breast Cancer Study Group)'. Together they form a unique fingerprint.

Cite this